387 related articles for article (PubMed ID: 23172668)
1. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.
Bocca C; Bozzo F; Cannito S; Parola M; Miglietta A
Mol Carcinog; 2012 Oct; 51(10):783-95. PubMed ID: 21882253
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
5. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC).
Zhao Q; Gu X; Zhang C; Lu Q; Chen H; Xu L
Cancer Biol Ther; 2015; 16(4):634-43. PubMed ID: 25778781
[TBL] [Abstract][Full Text] [Related]
6. Silencing of COX-2 by RNAi modulates epithelial-mesenchymal transition in breast cancer cells partially dependent on the PGE2 cascade.
Cao J; Yang X; Li WT; Zhao CL; Lv SJ
Asian Pac J Cancer Prev; 2014; 15(22):9967-72. PubMed ID: 25520137
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
8. Total flavone of
Yang BL; Zhu P; Li YR; Xu MM; Wang H; Qiao LC; Xu HX; Chen HJ
World J Gastroenterol; 2018 Aug; 24(30):3414-3425. PubMed ID: 30122880
[TBL] [Abstract][Full Text] [Related]
9. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
11. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
12. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
[TBL] [Abstract][Full Text] [Related]
13. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
14. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Reckamp KL; Gardner BK; Figlin RA; Elashoff D; Krysan K; Dohadwala M; Mao J; Sharma S; Inge L; Rajasekaran A; Dubinett SM
J Thorac Oncol; 2008 Feb; 3(2):117-24. PubMed ID: 18303430
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
Zhang A; Wang MH; Dong Z; Yang T
Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1323-31. PubMed ID: 16868306
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
Wen SL; Gao JH; Yang WJ; Lu YY; Tong H; Huang ZY; Liu ZX; Tang CW
J Gastroenterol Hepatol; 2014 Nov; 29(11):1932-42. PubMed ID: 24909904
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibition and lung cancer.
Sandler AB; Dubinett SM
Semin Oncol; 2004 Apr; 31(2 Suppl 7):45-52. PubMed ID: 15179623
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
Cha BK; Kim YS; Hwang KE; Cho KH; Oh SH; Kim BR; Jun HY; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2016 Aug; 7(35):57213-57227. PubMed ID: 27528025
[TBL] [Abstract][Full Text] [Related]
19. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
